Abivax Appoints Michael Nesrallah as Chief Commercial Officer
Abivax (ABVX) has appointed Michael Nesrallah as its chief commercial officer, Nesrallah will lead global commercial strategy and launch preparation as the company advances toward potential regulatory approval and market entry for obefazimod, bringing more than 20 years of global biopharmaceutical leadership experience with expertise in gastroenterology and immunology. Prior to joining Abivax, he held several senior leadership roles at Takeda (TAK).
